This month in gastroenterology Eugene B Chang  Gastroenterology  Volume 124, Issue 5, Pages 1173-1175 (May 2003) DOI: 10.1016/S0016-5085(03)00322-6

Figure 1 Kaplan-Meier estimates of cumulative pouchitis rates during treatment with (a) VSL#3 or (b) placebo. Gastroenterology 2003 124, 1173-1175DOI: (10.1016/S0016-5085(03)00322-6)

Figure 2 UC patients display impaired expression of PPARγ in colonic epithelial cells. PPARγ immunostainings (green) in sections obtained from (A) healthy controls, and noninflamed biopsy specimens from (B) CD and (C) UC patients respectively (magnification 250×). (D) Western blot analysis of PPARγ protein in purified epithelial cells from the colonic mucosa of representative control patient (control), CD, and UC patients. Gastroenterology 2003 124, 1173-1175DOI: (10.1016/S0016-5085(03)00322-6)

Figure 3 Forty-two-day mortality (top) and adverse events (bottom) irrespective of the vasoactive control treatment in full reports, according to whether adequate generation of the randomization list and adequate treatment allocation concealment were used or not. RCTs are identified by the first author and the year of publication. RD, risk difference; I, confidence interval; EVS, endoscopic variceal sclerotherapy. Gastroenterology 2003 124, 1173-1175DOI: (10.1016/S0016-5085(03)00322-6)

Figure 4 Immunohistochemical staining of hsp25 and hsp72 in jejunum and colon of normal C57Bl/6 mice. Paraffin sections of formalin-fixed tissue were stained for hsp25 and hsp72. Images shown are representative of all intestinal segments from 3 separate mice (original magnification, 200×). Gastroenterology 2003 124, 1173-1175DOI: (10.1016/S0016-5085(03)00322-6)